Gimv invests EUR4 million in biopharma company Topas Therapeutics
Gimv today announces a EUR 4 million investment in Topas Therapeutics, a biopharma company developing a unique immunotherapy approach to treat autoimmune diseases. This investment is part of a total Series A financing round of EUR 14 million from a consortium of specialised life sciences investors including Epidarex Capital, EMBL